AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma
Shots:
- AbbVie & Simcere Zaiming (subsidiary Simcere Pharma) have signed an option to license agreement for developing SIM0500, being assessed in P-I for r/r multiple myeloma (MM) in the US & China
- As per the terms, Simcere will get an upfront, up to $1.055B option fees & milestones plus net-sales-based tiered royalties outside Greater China while AbbVie is entitled for tiered royalties in Greater China
- SIM0500 (GPRC5D, BCMA & CD3 targeting TsAb) is developed by Simcere’s T-cell engager polyspecific Ab tech, consisting of a low-affinity CD3 arm & binding sites for GPRC5D & BCMA. It has depicted strong T-cell-mediated cytotoxicity against MM cells through a combination of antitumor mechanisms
Ref: AbbVie | Image: AbbVie & Simcere
Related News:- AbbVie to Bolster its Immunology Pipeline Through the Acquisition of Nimble Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
